Your browser doesn't support javascript.
loading
Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography.
Karnes, R Jeffrey; Murphy, Christopher R; Bergstralh, Eric J; DiMonte, Guy; Cheville, John C; Lowe, Val J; Mynderse, Lance A; Kwon, Eugene D.
Afiliación
  • Karnes RJ; Department of Urology, Mayo Clinic, Rochester, Minnesota. Electronic address: Karnes.r@mayo.edu.
  • Murphy CR; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Bergstralh EJ; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  • DiMonte G; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Cheville JC; Department of Pathology, Mayo Clinic, Rochester, Minnesota.
  • Lowe VJ; Department of Radiology, Mayo Clinic, Rochester, Minnesota.
  • Mynderse LA; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Kwon ED; Department of Urology, Mayo Clinic, Rochester, Minnesota.
J Urol ; 193(1): 111-6, 2015 Jan.
Article en En | MEDLINE | ID: mdl-25150640
ABSTRACT

PURPOSE:

We report salvage lymph node dissections for prostate cancer nodal recurrence detected by (11)C-choline positron emission tomography/computerized tomography in the setting of increasing prostate specific antigen after radical prostatectomy. MATERIALS AND

METHODS:

Retrospective chart review was performed for all patients who underwent salvage lymph node dissection for prostate cancer nodal recurrence. Only patients previously treated with radical prostatectomy were included in the study and those with evidence of local recurrence were excluded from analysis. Primary end points included biochemical recurrence, systemic progression and cancer specific mortality.

RESULTS:

From 2009 to 2013, 52 men underwent salvage lymph node dissection. Before salvage lymph node dissection 78.8% (41 of 52) had some form of therapy after radical prostatectomy. Median age at salvage lymph node dissection was 60 years and median prostate specific antigen was 2.2 ng/ml (IQR 1.4-3.7). The median number of lymph nodes dissected was 21.5 (IQR 16-30) and the median number of positive nodes was 3.5 (IQR 1.2-6.5). Since salvage lymph node dissection 46.2% of the men (24 of 52) have had no further treatment, 34.6% (18 of 52) are on hormonal therapy and 19.2% (10 of 52) have received multiple different treatments. At the last followup at a median of 20 months (IQR 8-33), 57.7% (30 of 52) had prostate specific antigen remain less than 0.2 ng/ml, 75% (39 of 52) remained free of systemic progression and 96.2% of the men (50 of 52) were alive. Two patients died of prostate cancer. Three-year biochemical recurrence-free, systemic progression-free and cancer specific survival was 45.5%, 46.9% and 92.5%, respectively.

CONCLUSIONS:

This represents the largest U.S. series of salvage lymph node dissection in the setting of lymph node metastatic prostate cancer after radical prostatectomy. Although followup was short and the study lacked a randomized control group, salvage lymph node dissection may represent a valid treatment option.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Radioisótopos de Carbono / Tomografía Computarizada por Rayos X / Colina / Tomografía de Emisión de Positrones / Imagen Multimodal / Escisión del Ganglio Linfático / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: J Urol Año: 2015 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Radioisótopos de Carbono / Tomografía Computarizada por Rayos X / Colina / Tomografía de Emisión de Positrones / Imagen Multimodal / Escisión del Ganglio Linfático / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: J Urol Año: 2015 Tipo del documento: Article